<DOC>
	<DOCNO>NCT00626288</DOCNO>
	<brief_summary>The purpose study determine whether Mesalazine effective treatment abdominal discomfort pain Irritable Bowel Syndrome patient .</brief_summary>
	<brief_title>Mesalazine Therapy Patients With Irritable Bowel Syndrome</brief_title>
	<detailed_description>The present study prospective , double blind , randomise , multicenter trial design study efficacy mesalazine treatment symptom IBS . In subgroup patient efficacy treatment also assess low-grade inflammation . We expect confirm mesalazine treatment reduces number activation inflammatory cell colonic mucosa IBS patient , thus provide rationale assessment treatment symptom IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>IBS patient positive diagnosis inclose Rome III criterion Any organic metabolic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Mesalazine Irritable Bowel Syndrome</keyword>
</DOC>